The influences of depression and venlafaxine use at therapeutic doses on atrial conduction

Journal of Psychopharmacology

Volumn 23, Issue 2, 2009, Pages 163-167

  Emul, M ^a   Dalkiran, M ^a   Samim, S ^a   Yildirim, E ^b   Bayar, R ^a   Balcioglu, I ^a   Keles, I ^b  

^a University Hospital of Afyon Kocatepe   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Depression; P wave dispersion; P wave duration; QTc; Venlafaxine

Indexed keywords

VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE;

ADULT; AGE; ARTICLE; BECK ANXIETY INVENTORY; BECK DEPRESSION INVENTORY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG OVERDOSE; ELECTROCARDIOGRAPHY; FEMALE; GENDER; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HUMAN; MALE; P WAVE; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; DRUG EFFECT; HEART ATRIUM; HEART ATRIUM FUNCTION; HEART MUSCLE CONDUCTION SYSTEM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ATRIAL FUNCTION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES;

EID: 67651173267     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089590     Document Type: Article

References (32)

1. Aytemir K, Hnatkova K, Malik M, (1999) Duration of the P wave dispersion in normal healthy population. Turk J Intervent Cardiol 3: 142 - 147.
2. Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, Oto A, Ozmen F, Kes S, (2000) P wave dispersion on 12-lead electrocardiography in patients with paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 23: 1109 - 1112.
3. B?Currency signr KJ, Greiner W, Jochum T, Friedrich M, Wagner G, Sauer H, (2004) The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord 82: 245 - 252.
4. Barnes RF, Veith RC, Borson S, Verhey J, Raskind MA, Halter JB, (1983) High levels of plasma catecholamines in dexamethasone-resistant depressed patients. Am J Psychiatry 140: 1623 - 1625 [].
5. Beck AT, Steer RA, (1987) Manual for the Revised Beck Depression Inventory. San Antonio, TX: Psychological Corporation.
6. Beck AT, Epstein N, Brown G, Steer RA, (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56: 893 - 897.
7. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS, (1993) Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 95: 23 - 28.
8. Carney RM, Freedland KE, Stein PK, Watkins LL, Catellier D, Jaffe AS, Yeragani VK, (2003) Effects of depression on QT interval variability after myocardial infarction. Psychosom Med 65: 177 - 180.
9. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS, (1995) Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 76: 562 - 564.
10. Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE, (2000) Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 23: 352 - 358.
11. Dilaveris PE, Gialafos EJ, Sideris S, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE, Toutouzas PK, (1998) Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 135: 733 - 738.
12. Dilaveris PE, Gialofos JE, (2001) P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 6: 159 - 165.
13. Elming H, Sonne J, Lublin HK, (2003) The importance of the QT interval: a review of the literature. Acta Psychiatr Scand 107: 96 - 101.
14. http://www.fda.gov/cder/guidance/6922fnl.htm
15. First MB, Spitzer RL, Gibbon M, Williams JB, (2001) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition, (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute.
16. First MB, Spitzer RL, Gibbon M, Williams JBW, (1996) Structured Clinical Interview for Axis I DSM-IV Disorders - Patient Version (SCID-1/P version 2.0). New York: New York State Psychiatric Institute Biometrics Research Department.
17. Harvey AT, Rudolph RL, Preskorn SH, (2000) Evidence of dual mechanism of action of venlafaxine. Arch Gen Psychiatry 57: 503 - 509.
18. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R, (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and Regulatory Implications Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47: 219 - 233.
19. Howell C; ,Wilson AD; ,Waring WS; , (2007) Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol (online early articles)64: 192-197.
20. Khalifa M, Daleau P, Turgeon J, (1999) Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 291: 280 - 284.
21. Kocer A, Karakaya O, Barutcu I, Esen OB, Kargin R, Domac M, (2006) Assesment of P wave duration and dispersion in Parkinson's disease. Prog Neur-Psychopharmacol and Biol Psychiatry 30: 718 - 723.
22. Lehofer M, Moser M, Hoehn-Saric R, McLeod D, Liebmann P, Drnovsek B, Egner S, Hildebrandt G, Zapotoczky H-G, (1997) Major depression and cardiac autonomic control. Biol Psychiatry 42: 914 - 919.
23. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F, (2006) Letter to the Editor: QT interval prolongation associated with venlafaxine administration. Int J Cardiol 109: 116 - 117.
24. Lindborg SR, Beasley CM, Alaka K, Taylor CC, (2003) Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res 119: 113 - 123.
25. Mbaya P, Alam F, Ashim S, Bennett D, (2007) Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol Clin Exp 22: 129 - 133.
26. Musselman DL, Evans DL, Nemeroff CB, (1998) The relationship of depression to cardiovascular disease: epidemiology, biology and treatment. Arch Gen Psychiatry 55: 580 - 592.
27. Muthe EA, Haskins JT, Moyer JA, Husbands GE, Neilsen ST, Sigg EB, (1986) Antidepressant biochemical profile of the novel bicyclic compound WY-45, 030,an ethyl cyclo hexanol derivative. Biochem Pharmacol 35: 4493 - 4497.
28. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, (2001) Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonine reuptake inhibitors in depressed patients. Ther Drug Monit 23: 435 - 440.
29. Taylor DM, (2003) Antipsychotics and QT prolongation. Acta Psychiatr Scand 107: 85 - 95.
30. Tukek T, Akaya V, Demirel S, Sozen AB, Kudat H, Atilgan D, Ozcan M, Guven O, Korkut F, (2000) Effect of valsalva maneuver on surface electrocardiographic P wave dispersion in paroxysmal atrial fibrillation. Am J Cardiol 85: 896 - 899.
31. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, Murburg MM, Ashleigh EA, Castillo S, Peskind ER, Pascualy M, Halter JB, (1994) Sympathetic nervous system activity in major depression. Arch Gen Psychiatry 51: 411 - 422 [].
32. Volkers AC, Tulen JHM, van den Broek WW, Bruijn JA, Passchier J, Pepplinkhuizen L, (2003) Motor activity and autonomic cardiac function in major depressive disorder. J Aff Disord 76: 23 - 30.